Mesenchymal stem cells for the treatment of CNS diseases

Patent metadata

Field	Value
Publication number	US-10052363-B2
Application number	US-201615261959-A
Country	US
Kind code	B2
Filing date	Sep 11, 2016
Priority date	May 28, 2008
Publication date	Aug 21, 2018
Grant date	Aug 21, 2018

Abstract

An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.

First claim

What is claimed is:

1. A method of treating a neurodegenerative disorder comprising administering to the central nervous system of an individual in need thereof a therapeutically effective amount of non-genetically modified human cells which express at least one mesenchymal stem cell marker and secrete brain-derived neurotrophic factor (BDNF) and glial derived neurotrophic factor (GDNF), and do not secrete nerve growth factor (bNGF), wherein said at least one mesenchymal stem cell marker is selected from the group consisting of CD73, CD90 and CD105, wherein a basal secretion of said GDNF in the cells is at least two times greater than a basal secretion of said GDNF in non-differentiated, non-genetically modified human mesenchymal stem cells, wherein the neurodegenerative disease is selected from the group consisting of Parkinson's Disease, amyotrophic lateral sclerosis (ALS) and Huntington's disease, wherein said non-genetically modified human cells are differentiated ex vivo from bone marrow derived mesenchymal stem cells.

2. The method of claim 1 , wherein said non-genetically modified human cells further express at least one additional neurotrophic factor.

3. The method of claim 2 , wherein said at least one additional neurotrophic factor is selected from the group consisting of neurotrophin-3 (NT-3), neurotrophin-4/5, neurturin (NTN), persephin, artemin (ART), ciliary neurotrophic factor (CNTF), insulin growth factor-I (IGF-1) and neublastin.

4. The method of claim 1 , wherein said non-genetically modified human cells take up at least ten times more glutamate from their surroundings than non-differentiated, non-genetically modified mesenchymal stem cells.

5. The method of claim 1 , wherein said non-genetically modified human cells are autologous to said subject.

6. The method of claim 1 , wherein said non-genetically modified human cells are non-autologous to said subject.

7. The method of claim 1 , wherein said non-genetically modified human cells are allogeneic to said subject.

Assignees

• Univ Ramot
• Brainstorm Cell Therapeutics Ltd

Inventors

• Kadouri Avinoam
• Bar-Ilan Avihay
• Melamed Eldad
• Offen Daniel
• Sadan Ofer
• Bahat-Stromza Merav

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• C12N2501/135

  Platelet-derived growth factor [PDGF] · CPC title

• A61K35/28

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title

• C12N2500/84

  from mammals · CPC title